证券代码：688222 证券简称：成都先导 公告编号：2026-003

Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 104 million to 127 million yuan, representing an increase of 52.64 million to 75.64 million yuan compared to the previous year, which is a year-on-year increase of 102.50% to 147.29% [1] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 106 million to 129 million yuan, an increase of 48.56 million to 71.56 million yuan year-on-year, translating to a growth of 84.55% to 124.59% [1] Previous Year Performance - In 2024, the company reported a total profit of 62.76 million yuan, with a net profit attributable to shareholders of the parent company at 51.36 million yuan, and a net profit after deducting non-recurring gains and losses at 57.44 million yuan [1] - The earnings per share for 2024 was 0.13 yuan [1] Main Reasons for Performance Change - The company has established long-term stable collaborations with global partners, leading to steady progress in commercial projects. The core business segment, DEL, has maintained steady growth and high gross margins, contributing to overall profit improvement. The UK subsidiary has further solidified the development of the FBDD/SBDD platform, with revenue growth from key business segments and milestone income from DEL and FBDD/SBDD projects [1] - The OBT segment has shown significant commercial transformation, with revenue growth driven by the expansion of traditional nucleotide monomer synthesis and the introduction of delivery molecule-related services. The automated high-throughput chemical synthesis platform has also operated efficiently, boosting revenue from ChemSer services [1]